{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:21Z","timestamp":1790800401521,"version":"4.1.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s11060-018-2990-6","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T03:51:45Z","timestamp":1535687505000},"page":"509-517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Characterization of genomic alterations in primary central nervous system lymphomas"],"prefix":"10.1007","volume":"140","author":[{"given":"Soheil","family":"Zorofchian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanadi","family":"El-Achi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9757-1453","authenticated-orcid":false,"given":"Yoshua","family":"Esquenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-6830","authenticated-orcid":false,"given":"Leomar Y.","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"2990_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young KH, Medeiros LJ (2018) Diffuse large B-cell lymphoma. Pathology 50:74\u201387. https:\/\/doi.org\/10.1016\/j.pathol.2017.09.006","journal-title":"Pathology"},{"key":"2990_CR2","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937\u20131947. https:\/\/doi.org\/10.1056\/NEJMoa012914","journal-title":"N Engl J Med"},{"key":"2990_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","volume":"131","author":"K Fukumura","year":"2016","unstructured":"Fukumura K, Kawazu M, Kojima S et al (2016) Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol 131:865\u2013875. https:\/\/doi.org\/10.1007\/s00401-016-1536-2","journal-title":"Acta Neuropathol"},{"key":"2990_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cncr.21562","volume":"106","author":"C Diamond","year":"2006","unstructured":"Diamond C, Taylor TH, Aboumrad T, Anton Culver H (2006) Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 106:128\u2013135. https:\/\/doi.org\/10.1002\/cncr.21562","journal-title":"Cancer"},{"key":"2990_CR5","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1182\/blood.V98.8.2339","volume":"98","author":"C Besson","year":"2001","unstructured":"Besson C, Goubar A, Gabarre J et al (2001) Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 98:2339\u20132344","journal-title":"Blood"},{"key":"2990_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjh.14073","volume":"174","author":"MS Shiels","year":"2016","unstructured":"Shiels MS, Pfeiffer RM, Besson C et al (2016) Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br J Haematol 174:417\u2013424. https:\/\/doi.org\/10.1111\/bjh.14073","journal-title":"Br J Haematol"},{"key":"2990_CR7","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570\u20134574. https:\/\/doi.org\/10.1200\/JCO.2006.06.6910","journal-title":"J Clin Oncol"},{"key":"2990_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/neuonc\/nor014","volume":"13","author":"L Nayak","year":"2011","unstructured":"Nayak L, Hedvat C, Rosenblum MK et al (2011) Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro-oncology 13:525\u2013529. https:\/\/doi.org\/10.1093\/neuonc\/nor014","journal-title":"Neuro-oncology"},{"key":"2990_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/neup.12405","volume":"37","author":"M Zheng","year":"2017","unstructured":"Zheng M, Perry AM, Bierman P et al (2017) Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma. Neuropathology 37:509\u2013516. https:\/\/doi.org\/10.1111\/neup.12405","journal-title":"Neuropathology"},{"key":"2990_CR10","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.3109\/10428194.2014.979413","volume":"56","author":"S Yamada","year":"2015","unstructured":"Yamada S, Ishida Y, Matsuno A, Yamazaki K (2015) Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma 56:2141\u20132145. https:\/\/doi.org\/10.3109\/10428194.2014.979413","journal-title":"Leuk Lymphoma"},{"key":"2990_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/nan.12259","volume":"42","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Tateishi K, Niwa T et al (2016) Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol 42:279\u2013290. https:\/\/doi.org\/10.1111\/nan.12259","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2990_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470:115\u2013119. https:\/\/doi.org\/10.1038\/nature09671","journal-title":"Nature"},{"key":"2990_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","volume":"246","author":"K-H Lim","year":"2012","unstructured":"Lim K-H, Yang Y, Staudt LM (2012) Pathogenetic importance and therapeutic implications of NF-\u03baB in lymphoid malignancies. Immunol Rev 246:359\u2013378. https:\/\/doi.org\/10.1111\/j.1600-065X.2012.01105.x","journal-title":"Immunol Rev"},{"key":"2990_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/35092578","volume":"413","author":"KA Fitzgerald","year":"2001","unstructured":"Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al (2001) Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 413:78\u201383. https:\/\/doi.org\/10.1038\/35092578","journal-title":"Nature"},{"key":"2990_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","volume":"122","author":"M Montesinos-Rongen","year":"2011","unstructured":"Montesinos-Rongen M, Godlewska E, Brunn A et al (2011) Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 122:791\u2013792. https:\/\/doi.org\/10.1007\/s00401-011-0891-2","journal-title":"Acta Neuropathol"},{"key":"2990_CR16","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","volume":"21","author":"E Braggio","year":"2015","unstructured":"Braggio E, Van Wier S, Ojha J et al (2015) Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res 21:3986\u20133994. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2116","journal-title":"Clin Cancer Res"},{"key":"2990_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/leu.2014.264","volume":"29","author":"I Vater","year":"2015","unstructured":"Vater I, Montesinos-Rongen M, Schlesner M et al (2015) The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia 29:677\u2013685. https:\/\/doi.org\/10.1038\/leu.2014.264","journal-title":"Leukemia"},{"key":"2990_CR18","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","volume":"18","author":"A Gonzalez-Aguilar","year":"2012","unstructured":"Gonzalez-Aguilar A, Idbaih A, Boisselier B et al (2012) Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 18:5203\u20135211. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0845","journal-title":"Clin Cancer Res"},{"key":"2990_CR19","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom QT, Gittleman H, Liao P et al (2017) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014. Neuro-oncology 19:v1\u2013v88. https:\/\/doi.org\/10.1093\/neuonc\/nox158","journal-title":"Neuro-oncology"},{"key":"2990_CR20","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.ejrad.2016.07.005","volume":"85","author":"S Lu","year":"2016","unstructured":"Lu S, Gao Q, Yu J et al (2016) Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor. Eur J Radiol 85:1722\u20131727. https:\/\/doi.org\/10.1016\/j.ejrad.2016.07.005","journal-title":"Eur J Radiol"},{"key":"2990_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/leu.2016.166","volume":"31","author":"K Wang","year":"2017","unstructured":"Wang K, Sanchez-Martin M, Wang X et al (2017) Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia 31:151\u2013158. https:\/\/doi.org\/10.1038\/leu.2016.166","journal-title":"Leukemia"},{"key":"2990_CR22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4","journal-title":"Lancet"},{"key":"2990_CR23","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L et al (2017) Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther 16:2598\u20132608. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0386","journal-title":"Mol Cancer Ther"},{"key":"2990_CR24","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102","journal-title":"Proc Natl Acad Sci USA"},{"key":"2990_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"2990_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41598-017-00767-8","volume":"7","author":"J-H Lee","year":"2017","unstructured":"Lee J-H, Jeong H, Choi J-W et al (2017) Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Sci Rep 7:659. https:\/\/doi.org\/10.1038\/s41598-017-01998-5","journal-title":"Sci Rep"},{"key":"2990_CR27","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1038\/bcj.2013.28","volume":"3","author":"W Kraan","year":"2013","unstructured":"Kraan W, Horlings HM, van Keimpema M et al (2013) High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 3:e139\u2013e139. https:\/\/doi.org\/10.1038\/bcj.2013.28","journal-title":"Blood Cancer J"},{"key":"2990_CR28","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","volume":"123","author":"SP Treon","year":"2014","unstructured":"Treon SP, Cao Y, Xu L et al (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123:2791\u20132796. https:\/\/doi.org\/10.1182\/blood-2014-01-550905","journal-title":"Blood"},{"key":"2990_CR29","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bjh.13293","volume":"170","author":"S Poulain","year":"2015","unstructured":"Poulain S, Boyle EM, Tricot S et al (2015) Absence of CXCR4 mutations but high incidence of double mutant in CD79A\/B and MYD88 in primary central nervous system lymphoma. Br J Haematol 170:285\u2013287. https:\/\/doi.org\/10.1111\/bjh.13293","journal-title":"Br J Haematol"},{"key":"2990_CR30","doi-asserted-by":"publisher","first-page":"vi175","DOI":"10.1093\/neuonc\/nox168.711","volume":"19","author":"E Severson","year":"2017","unstructured":"Severson E, Vergilio J-A, Gay L et al (2017) PATH-20. Comprehensive genomic profiling comparing primary CNS lymphoma to systemic diffuse large B cell lymphoma reveals biomarkers indicating potential benefit from immune checkpoint inhibitors. Neuro-oncology 19:vi175\u2013vi175. https:\/\/doi.org\/10.1093\/neuonc\/nox168.711","journal-title":"Neuro-oncology"},{"key":"2990_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","volume":"49","author":"UM Domanska","year":"2013","unstructured":"Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4\/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219\u2013230. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.005","journal-title":"Eur J Cancer"},{"key":"2990_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/leu.2014.187","volume":"29","author":"Y Cao","year":"2015","unstructured":"Cao Y, Hunter ZR, Liu X et al (2015) The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s Macroglobulinemia. Leukemia 29:169\u2013176. https:\/\/doi.org\/10.1038\/leu.2014.187","journal-title":"Leukemia"},{"key":"2990_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.13200","volume":"168","author":"Y Cao","year":"2015","unstructured":"Cao Y, Hunter ZR, Liu X et al (2015) CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells. Br J Haematol 168:701\u2013707. https:\/\/doi.org\/10.1111\/bjh.13200","journal-title":"Br J Haematol"},{"key":"2990_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MOH.0b013e328338b7d5","volume":"17","author":"I Pusic","year":"2010","unstructured":"Pusic I, DiPersio JF (2010) Update on clinical experience with AMD3100, an SDF-1\/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 17:319\u2013326. https:\/\/doi.org\/10.1097\/MOH.0b013e328338b7d5","journal-title":"Curr Opin Hematol"},{"key":"2990_CR35","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1111\/j.1582-4934.2010.01210.x","volume":"15","author":"DH McDermott","year":"2011","unstructured":"McDermott DH, Lopez J, Deng F et al (2011) AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med 15:2071\u20132081. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01210.x","journal-title":"J Cell Mol Med"},{"key":"2990_CR36","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","volume":"123","author":"A Mart\u00ednez-Trillos","year":"2014","unstructured":"Mart\u00ednez-Trillos A, Pinyol M, Navarro A et al (2014) Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood 123:3790\u20133796. https:\/\/doi.org\/10.1182\/blood-2013-12-543306","journal-title":"Blood"},{"key":"2990_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/cas.13450","volume":"109","author":"K Hattori","year":"2018","unstructured":"Hattori K, Sakata-Yanagimoto M, Suehara Y et al (2018) Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci 109:225\u2013230. https:\/\/doi.org\/10.1111\/cas.13450","journal-title":"Cancer Sci"},{"key":"2990_CR38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMc1506192","volume":"373","author":"SP Treon","year":"2015","unstructured":"Treon SP, Xu L, Hunter Z (2015) MYD88 mutations and response to ibrutinib in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med 373:584\u2013586. https:\/\/doi.org\/10.1056\/NEJMc1506192","journal-title":"N Engl J Med"},{"key":"2990_CR39","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922\u2013926. https:\/\/doi.org\/10.1038\/nm.3884","journal-title":"Nat Med"},{"key":"2990_CR40","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1002\/hon.2489","volume":"21","author":"LS Hiemcke-Jiwa","year":"2017","unstructured":"Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH et al (2017) The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol 21:E7. https:\/\/doi.org\/10.1002\/hon.2489","journal-title":"Hematol Oncol"},{"key":"2990_CR41","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.18632\/oncotarget.2080","volume":"5","author":"A Bruno","year":"2014","unstructured":"Bruno A, Boisselier B, Labreche K et al (2014) Mutational analysis of primary central nervous system lymphoma. Oncotarget 5:5065\u20135075. https:\/\/doi.org\/10.18632\/oncotarget.2080","journal-title":"Oncotarget"},{"key":"2990_CR42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MGM, Stewart C et al (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869\u2013881. https:\/\/doi.org\/10.1182\/blood-2015-10-673236","journal-title":"Blood"},{"key":"2990_CR43","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.humpath.2012.10.026","volume":"44","author":"J-W Choi","year":"2013","unstructured":"Choi J-W, Kim Y, Lee J-H, Kim Y-S (2013) MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 44:1375\u20131381. https:\/\/doi.org\/10.1016\/j.humpath.2012.10.026","journal-title":"Hum Pathol"},{"key":"2990_CR44","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/j.wneu.2017.12.028","volume":"112","author":"S Takano","year":"2018","unstructured":"Takano S, Hattori K, Ishikawa E et al (2018) MyD88 mutation in elderly predicts poor prognosis in primary central nervous system lymphoma: multi-institutional analysis. World Neurosurg 112:e69\u2013e73. https:\/\/doi.org\/10.1016\/j.wneu.2017.12.028","journal-title":"World Neurosurg"},{"key":"2990_CR45","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/blood.V94.5.1773","volume":"94","author":"AS Baur","year":"1999","unstructured":"Baur AS, Shaw P, Burri N et al (1999) Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 94:1773\u20131781","journal-title":"Blood"},{"key":"2990_CR46","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/gcc.21970","volume":"51","author":"S Guney","year":"2012","unstructured":"Guney S, Jardin F, Bertrand P et al (2012) Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes. Genes Chromosomes Cancer 51:858\u2013867. https:\/\/doi.org\/10.1002\/gcc.21970","journal-title":"Genes Chromosomes Cancer"},{"key":"2990_CR47","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/0092-8674(95)90214-7","volume":"83","author":"DE Quelle","year":"1995","unstructured":"Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993\u20131000","journal-title":"Cell"},{"key":"2990_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.mrfmmm.2004.08.021","volume":"576","author":"NE Sharpless","year":"2005","unstructured":"Sharpless NE (2005) INK4a\/ARF: a multifunctional tumor suppressor locus. Mutat Res 576:22\u201338. https:\/\/doi.org\/10.1016\/j.mrfmmm.2004.08.021","journal-title":"Mutat Res"},{"key":"2990_CR49","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1038\/sj.onc.1202998","volume":"18","author":"MF Roussel","year":"1999","unstructured":"Roussel MF (1999) The INK4 family of cell cycle inhibitors in cancer. Oncogene 18:5311\u20135317. https:\/\/doi.org\/10.1038\/sj.onc.1202998","journal-title":"Oncogene"},{"key":"2990_CR50","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1158\/1078-0432.CCR-13-1551","volume":"20","author":"MA Dickson","year":"2014","unstructured":"Dickson MA (2014) Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 20:3379\u20133383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1551","journal-title":"Clin Cancer Res"},{"key":"2990_CR51","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-14-2258","volume":"21","author":"A DeMichele","year":"2015","unstructured":"DeMichele A, Clark AS, Tan KS et al (2015) CDK 4\/6 inhibitor palbociclib (PD0332991) in Rb + advanced breast cancer: phase II activity, safety, and predictive biomarker assessment. Clin Cancer Res 21:995\u20131001. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2258","journal-title":"Clin Cancer Res"},{"key":"2990_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16:25\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)71159-3","journal-title":"Lancet Oncol"},{"key":"2990_CR53","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/1078-0432.CCR-16-1248","volume":"22","author":"JR Infante","year":"2016","unstructured":"Infante JR, Cassier PA, Gerecitano JF et al (2016) A phase I study of the cyclin-dependent kinase 4\/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res 22:5696\u20135705. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1248","journal-title":"Clin Cancer Res"},{"key":"2990_CR54","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1634\/theoncologist.2014-0011","volume":"19","author":"DB Johnson","year":"2014","unstructured":"Johnson DB, Dahlman KH, Knol J et al (2014) Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist 19:616\u2013622. https:\/\/doi.org\/10.1634\/theoncologist.2014-0011","journal-title":"Oncologist"},{"key":"2990_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1101\/sqb.2005.70.004","volume":"70","author":"CJ SHERR","year":"2005","unstructured":"SHERR CJ, BESTEN den BERTWISTLED W, et al (2005) p53-dependent and -independent functions of the arf tumor suppressor. Cold Spring Harb Symp Quant Biol 70:129\u2013137. https:\/\/doi.org\/10.1101\/sqb.2005.70.004","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2990_CR56","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/ijc.25511","volume":"127","author":"P Ozenne","year":"2010","unstructured":"Ozenne P, Eymin B, Brambilla E, Gazzeri S (2010) The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer 127:2239\u20132247. https:\/\/doi.org\/10.1002\/ijc.25511","journal-title":"Int J Cancer"},{"key":"2990_CR57","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C et al (2012) Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL rituximab-CHOP Consortium Program Study. Blood 120:3986\u20133996. https:\/\/doi.org\/10.1182\/blood-2012-05-433334","journal-title":"Blood"},{"key":"2990_CR58","doi-asserted-by":"publisher","first-page":"e80023","DOI":"10.1371\/journal.pone.0080023","volume":"8","author":"NJ Birkbak","year":"2013","unstructured":"Birkbak NJ, Kochupurakkal B, Izarzugaza JMG et al (2013) Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS ONE 8:e80023. https:\/\/doi.org\/10.1371\/journal.pone.0080023","journal-title":"PLoS ONE"},{"key":"2990_CR59","doi-asserted-by":"publisher","first-page":"CT082","DOI":"10.1158\/1538-7445.AM2017-CT082","volume":"77","author":"S Peters","year":"2017","unstructured":"Peters S, Creelan B, Hellmann MD et al (2017) Abstract CT082: impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026. Cancer Res 77:CT082\u2013CT082. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-CT082","journal-title":"Cancer Res"},{"key":"2990_CR60","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrc3816","volume":"14","author":"SA Roberts","year":"2014","unstructured":"Roberts SA, Gordenin DA (2014) Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 14:786\u2013800. https:\/\/doi.org\/10.1038\/nrc3816","journal-title":"Nat Rev Cancer"},{"key":"2990_CR61","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A et al (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124\u2013128. https:\/\/doi.org\/10.1126\/science.aaa1348","journal-title":"Science"},{"key":"2990_CR62","doi-asserted-by":"publisher","first-page":"7435","DOI":"10.1038\/sj.onc.1205803","volume":"21","author":"GP Pfeifer","year":"2002","unstructured":"Pfeifer GP, Denissenko MF, Olivier M et al (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21:7435\u20137451. https:\/\/doi.org\/10.1038\/sj.onc.1205803","journal-title":"Oncogene"},{"key":"2990_CR63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mrfmmm.2004.06.057","volume":"571","author":"GP Pfeifer","year":"2005","unstructured":"Pfeifer GP, You Y-H, Besaratinia A (2005) Mutations induced by ultraviolet light. Mutat Res 571:19\u201331. https:\/\/doi.org\/10.1016\/j.mrfmmm.2004.06.057","journal-title":"Mutat Res"},{"key":"2990_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2","journal-title":"Genome Med"},{"key":"2990_CR65","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1158\/1538-7445.AM2017-3724","volume":"77","author":"LA Karim","year":"2017","unstructured":"Karim LA, Wang P, de Guzman J et al (2017) Abstract 3724: PDL1 protein expression and tumor mutation burden in hematologic malignancies: correlation with Hodgkin and high grade lymphoma. Cancer Res 77:3724\u20133724. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-3724","journal-title":"Cancer Res"},{"key":"2990_CR66","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2008-04-149005","volume":"113","author":"M Montesinos-Rongen","year":"2009","unstructured":"Montesinos-Rongen M, Siebert R, Deckert M (2009) Primary lymphoma of the central nervous system: just DLBCL or not? Blood 113:7\u201310. https:\/\/doi.org\/10.1182\/blood-2008-04-149005","journal-title":"Blood"},{"key":"2990_CR67","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1200\/JCO.2008.16.1455","volume":"26","author":"FM Cady","year":"2008","unstructured":"Cady FM, O\u2019Neill BP, Law ME et al (2008) Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 26:4814\u20134819. https:\/\/doi.org\/10.1200\/JCO.2008.16.1455","journal-title":"J Clin Oncol"},{"key":"2990_CR68","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1750-3639.2003.tb00483.x","volume":"13","author":"M Montesinos-Rongen","year":"2003","unstructured":"Montesinos-Rongen M, Akasaka T, Z\u00fchlke-Jenisch R et al (2003) Molecular characterization of BCL6 breakpoints in primary diffuse large B-cell lymphomas of the central nervous system identifies GAPD as novel translocation partner. Brain Pathol 13:534\u2013538","journal-title":"Brain Pathol"},{"key":"2990_CR69","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1093\/jnen\/61.10.926","volume":"61","author":"M Montesinos-Rongen","year":"2002","unstructured":"Montesinos-Rongen M, Z\u00fchlke-Jenisch R, Gesk S et al (2002) Interphase cytogenetic analysis of lymphoma-associated chromosomal breakpoints in primary diffuse large B-cell lymphomas of the central nervous system. J Neuropathol Exp Neurol 61:926\u2013933","journal-title":"J Neuropathol Exp Neurol"},{"key":"2990_CR70","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood.V92.9.3152","volume":"92","author":"MH Kramer","year":"1998","unstructured":"Kramer MH, Hermans J, Wijburg E et al (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152\u20133162","journal-title":"Blood"},{"key":"2990_CR71","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1002\/cncr.27396","volume":"118","author":"N Akyurek","year":"2012","unstructured":"Akyurek N, Uner A, Benekli M, Barista I (2012) Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 118:4173\u20134183. https:\/\/doi.org\/10.1002\/cncr.27396","journal-title":"Cancer"},{"key":"2990_CR72","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","volume":"121","author":"H Horn","year":"2013","unstructured":"Horn H, Ziepert M, Becher C et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253\u20132263. https:\/\/doi.org\/10.1182\/blood-2012-06-435842","journal-title":"Blood"},{"key":"2990_CR73","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/hon.2437_7","volume":"35","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene Ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-hodgkin lymphomas (NHL): primary results of the pivotal trial ZUMA-1. Hematol Oncol 35:28\u201328. https:\/\/doi.org\/10.1002\/hon.2437_7","journal-title":"Hematol Oncol"},{"key":"2990_CR74","doi-asserted-by":"publisher","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2017-CT019","volume":"77","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL et al (2017) Abstract CT019: primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Cancer Res 77:CT019\u2013CT019. https:\/\/doi.org\/10.1158\/1538-7445.AM2017-CT019","journal-title":"Cancer Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-018-2990-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-018-2990-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:56:44Z","timestamp":1571806604000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-018-2990-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2990"],"URL":"https:\/\/doi.org\/10.1007\/s11060-018-2990-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"18 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informal consent"}}]}}